Venatorx and Menarini enter commercial agreement for cefepime-taniborbactam
Betsy Goodfellow | January 11, 2024 | News story | Sales and Marketing | Infections and infestations, Menarini Group, Venatorx Pharmaceuticals, cefepime-taniborbactam, collaboration
Venatorx Pharmaceuticals and Menarini Group have announced that they have entered into a commercial agreement valid in 96 countries in Europe, Latin America, the Middle East, Turkey, North Africa and the Commonwealth of Independent States (CIS), under which Menarini will have the exclusive rights to commercialise cefepime-taniborbactam.
The drug is an investigational intravenous (IV) beta-lacta,/beta-lactamase inhibitor (BL/BLI) antibiotic combination which is in development for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)>
Christopher J Burns PhD, chief executive officer at Venatorx, commented: “With its global commercial infrastructure and significant experience in commercialising infectious disease products, including antibiotics, Menarini is ideally positioned to bring cefepime-taniborbactam to key geographic markets. Development of novel antibiotics with comprehensive resistance coverage is necessary to address critical global unmet medical needs and provide hope for patients and healthcare providers alike to effectively treat the rapidly growing number of drug-resistant gram-negative infections.”
Elcin Barker Ergun, chief executive officer of the Menarini Group, added: “At Menarini, we believe that the addition of cefepime-taniborbactam expands our existing AMR anti infectives portfolio and provides the opportunity to further strengthen our building of an important antibiotics portfolio focused on the critical pathogens responsible for the vast majority of antibiotic resistance. By leveraging our expertise and Menarini’s expansive commercial infrastructure, we will provide the resources needed to optimize the commercialisation, upon approval of relevant health authorities, of cefepime-taniborbactam and ensure patient access to this medicine across our global footprint.”
Betsy Goodfellow
Related Content
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Eisai and EcoNaviSta enter dementia collaboration
Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating …
GSK and CureVac to restructure collaboration into licensing agreement
GSK and CureVac have announced that they have restructured their existing collaboration into a license …
